Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity

Details

• Personal Author:
  Buragamadagu B ; Johnston RA ; Pilkington AW IV
• Description:
  Purpose of Review: To discuss the effectiveness of biologics, some of which comprise the newest class of asthma controller medications, and non-biologics in the treatment of asthma co-existing with obesity. Recent Findings: Our review of recent preliminary and published data from clinical trials revealed that obese asthmatics respond favorably to dupilumab, mepolizumab, omalizumab, and tezepelumab, which are biologics currently indicated as add-on maintenance therapy for severe asthma. Furthermore, clinical trials are ongoing to assess the efficacy of non-biologics in the treatment of obese asthma, including a glucagon-like peptide-1 receptor agonist, a Janus kinase inhibitor, and probiotics. Summary: Although many biologics presently indicated as add-on maintenance therapy for severe asthma exhibit efficacy in obese asthmatics, other phenotypes of asthma co-existing with obesity may be refractory to these medications. Thus, to improve quality of life and asthma control, it is imperative to identify therapeutic options for all existing phenotypes of obese asthma. [Description provided by NIOSH]
• Subjects:
  Asthma Asthma, Occupational Biopharmaceutics Occupational Health Safety
• Keywords:
  Author Keywords: Asthma Biologic Clinical Trial Forced Expiratory Volume In One Second Medical Treatment Obesity Pharmaceuticals Prescription Drugs Probiotic
• ISSN:
  1529-7322
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  OSHA Region 3 ; West Virginia
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  HELD - Health Effects Laboratory Division
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  381-393
• Volume:
  24
• Issue:
  7
• NIOSHTIC Number:
  nn:20069818
• Citation:
  Curr Allergy Asthma Rep 2024 Jul; 24(7):381-393
• Contact Point Address:
  Richard A. Johnston, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1000 Frederick Lane, Morgantown, WV, 26508-5402, USA
• Email:
  rfj1@cdc.gov
• Federal Fiscal Year:
  2024
• Peer Reviewed:
  True
• Source Full Name:
  Current Allergy & Asthma Reports
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:a8ea934de368712be7a8f2415c383e5892f89e250d1fa34ac5743645217e48b977bfd046f137e7d1d5b9bec8c8b1a4cf58d3e18d9bc909e8e86f0f78aff840d9
• Download URL:
  https://stacks.cdc.gov/view/cdc/208170/cdc_208170_DS1.pdf
• File Type:
  [PDF - 2.04 MB ]